Xie, Xiong
Lan, Qiaoshuai http://orcid.org/0000-0001-5524-3542
Zhao, Jinyi http://orcid.org/0000-0002-5119-359X
Zhang, Sulin http://orcid.org/0000-0002-9167-4689
Liu, Lu
Zhang, Yumin http://orcid.org/0000-0003-0767-1221
Xu, Wei
Shao, Maolin
Peng, Jingjing
Xia, Shuai
Zhu, Yan
Zhang, Keke
Zhang, Xianglei http://orcid.org/0000-0001-5175-8311
Zhang, Ruxue
Li, Jian
Dai, Wenhao
Ge, Zhen
Hu, Shulei
Yu, Changyue
Wang, Jiang http://orcid.org/0000-0003-1705-4905
Ma, Dakota
Zheng, Mingyue http://orcid.org/0000-0002-3323-3092
Yang, Haitao http://orcid.org/0000-0002-1875-3268
Xiao, Gengfu http://orcid.org/0000-0001-9401-235X
Rao, Zihe
Lu, Lu http://orcid.org/0000-0002-2255-0391
Zhang, Leike http://orcid.org/0000-0002-2593-2571
Bai, Fang http://orcid.org/0000-0003-1468-5568
Zhao, Yao http://orcid.org/0000-0002-2932-2164
Jiang, Shibo http://orcid.org/0000-0001-8283-7135
Liu, Hong http://orcid.org/0000-0003-3685-6268
Article History
Received: 12 July 2023
Revised: 19 January 2024
Accepted: 25 January 2024
First Online: 6 March 2024
Competing interests
: The Shanghai Institute of Materia Medica has applied for PCT and Chinese patents that cover <b>14a</b>, <b>14b</b> and related peptidomimetic α-ketoamide compounds.